Evogene Ltd represents values of innovation, sustainability, and collaboration. With a strong corporate philosophy, Evogene is committed to developing cutting-edge technologies in the fields of agroscience and crop improvement. By harnessing the power of computational biology and advanced genomic technologies, Evogene strives to address global challenges in food security and sustainable agriculture. The company focuses on partnerships and collaborations with leading industry players to drive the development and commercialization of its innovative solutions. Through its dedication to scientific excellence and a sustainable future, Evogene Ltd aims to revolutionize the agricultural industry and ensure a more productive and resilient food supply.

Evogene Ltd is primarily present in Israel and has a significant presence in the United States as well.

Evogene Ltd has achieved significant milestones in its journey. Over the years, the company has made remarkable progress and accomplishments. Some notable milestones include the successful development and commercialization of innovative agricultural traits and products. Evogene has also established important collaborations and partnerships with leading companies and organizations in the industry. Through its advanced computational biology and predictive biology capabilities, Evogene has consistently delivered cutting-edge solutions and technologies for enhancing crop productivity and agricultural sustainability. These achievements have solidified Evogene's position as a pioneering player in the field, driving growth and value creation for the company and its stakeholders.

Evogene Ltd is an Israeli biotechnology company focused on improving crop productivity and sustainability. Established in 2002, Evogene has developed advanced computational genomics technologies to enhance various traits in crops. By leveraging its proprietary computational biology platform, the company identifies and validates novel genes, leading to the development of improved seeds and agrochemical products. Evogene collaborates with leading seed companies and crop protection firms to bring innovative solutions to the market. With a strong emphasis on research and development, Evogene continues to drive advancements in the agricultural sector, aiming to address global food and environmental challenges through cutting-edge technology.

The main competitors of Evogene Ltd in the market include companies such as Monsanto Company, Bayer AG, and Syngenta AG. These companies operate in the same biotechnology sector and compete with Evogene in various aspects, including agricultural research and development, genetically modified products, and crop protection solutions. Evogene Ltd faces competition from these major global players as they strive to capture a significant share of the market and deliver innovative solutions for sustainable agriculture.

Evogene Ltd is primarily active in the fields of agriculture and biotechnology.

The business model of Evogene Ltd revolves around leveraging advanced biotechnology to develop innovative agricultural solutions. Evogene specializes in computational biology, genomics, and predictive algorithms to accelerate seed and crop improvement processes. Through strategic collaborations with leading seed and agrochemical companies, Evogene aims to provide sustainable and high-performing crop traits that enhance productivity, yield, and quality. By utilizing its proprietary technologies, Evogene strives to address challenges faced by farmers and the agriculture industry, such as improving crop resilience, combating diseases, and increasing nutritional value. Evogene's business model focuses on applying cutting-edge science to drive agricultural innovation and create value for its customers.

Det Evogene P/E-forhold er -0,02.

Evogene KUV er 0,32.

AlleAktien Kvalitetsscore for Evogene er 5/10.

Den forventede Evogene omsætning er 15,75 mio. USD.

Den forventede Evogene indtjening er -214,11 mio. USD.

Evogene Ltd is a leading company in the agricultural biotechnology industry that specializes in discovering and developing new solutions for the challenges of global agriculture. The business model of Evogene is divided into various divisions that are closely interconnected and form the core of the company's operations. One important division is the genomics technology platform that Evogene uses to create models for plants that can increase their resistance to diseases, pests, and environmental stress. Another important area for Evogene is the development of new products for agriculture based on their genomics technology. Evogene collaborates with leading agricultural corporations to develop seeds and other plant products that are tailored to the specific needs of agriculture. One of Evogene's key products is the Insect Control Trait (ICT), which was developed based on RNA interference. ICT is a revolutionary method for controlling pests that allows targeting and elimination of specific genes in the insect's food system. The company also has a division dedicated to the development of fertilizers and other products aimed at increasing crop yield and quality results. Evogene works with universities and research institutions to develop new methods for soil optimization and plant nutrition. In addition to these various divisions, Evogene also has a strong focus on research and development to ensure constant innovation of the offered products and technologies. The company relies on close collaboration with its customers and partners to meet the specific needs of agriculture. In summary, Evogene's business model is geared towards providing sustainable and innovative solutions for the challenges of global agriculture. With its focus on genomics technology and close collaboration with customers and partners, Evogene is well positioned to continue growing and expanding in this field.

Evogene udbetaler et udbytte på 0 USD fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Evogene, eller selskabet udbetaler ikke udbytte.

ISIN'en for Evogene er IL0011050551.

WKN for Evogene er A0Q7UP.

Tickeren for Evogene er EVGN.

I løbet af de sidste 12 måneder betalte Evogene en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil Evogene sandsynligvis betale en dividende på 0 USD.

Udbytteafkastet for Evogene er i øjeblikket .

Evogene betaler kvartalsvis udbytte. Dette uddeles i månederne .

Evogene betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 USD. Dette svarer til et dividendeafkast på 0 %.

Evogene bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Evogene fra den 8.8.2024 på 0 USD, skulle du have haft aktien i din portefølje før ex-datoen den 8.8.2024.

Udbetalingen af det sidste udbytte blev foretaget den 8.8.2024.

I løbet af 2023 udbetalte Evogene 0 USD i form af dividender.

Udbytterne fra Evogene udbetales i USD.